AIDS in Africa

Updated October 29, 2001

Raymond W. Copson
Foreign Affairs, Defense, and Trade Division
CONTENTS

SUMMARY

MOST RECENT DEVELOPMENTS

BACKGROUND AND ANALYSIS

Characteristics of the African Epidemic

Explaining the African Epidemic

Social and Economic Consequences

Responses to the AIDS Epidemic
  Effectiveness of the Response
  AIDS Treatment Issues

U.S. Policy
  Bush Administration
  Legislative Action

LEGISLATION
SUMMARY

Sub-Saharan Africa has been far more severely affected by AIDS than any other part of the world. The United Nations reports that 25.3 million adults and children are infected with the HIV virus in the region, which has about 10% of the world’s population but more than 70% of the worldwide total of infected people. The overall rate of infection among adults in sub-Saharan Africa is about 8.8%, compared with a 1.1% infection rate worldwide. Sixteen countries, mostly in eastern and southern Africa, have HIV infection rates of more than 10%, and the rate has reached 35.8% in Botswana. An estimated 17 million Africans have lost their lives to AIDS, including 2.4 million who died in 2000. AIDS has surpassed malaria as the leading cause of death in Africa, and it kills many times more Africans than war. In Africa, HIV is spread primarily by heterosexual contact, and sub-Saharan Africa is the only region where women are infected at a higher rate than men.

Experts relate the severity of the African AIDS epidemic to the region’s poverty. Health systems are ill-equipped for prevention, diagnosis, and treatment. Poverty forces many men to become migrant workers in urban areas, where they may have multiple sex partners. Poverty leads many women to become commercial sex workers, vastly increasing their risk of infection. Cultural and behavior patterns, such as low rates of male circumcision, may also play a role.

AIDS is having severe social and economic consequences, depriving Africa of skilled workers and teachers, while reducing life expectancy by decades in some countries. The cumulative total of African children orphaned by AIDS since the epidemic began is 12.1 million. Currently 6.5 million AIDS orphans are living in Africa, facing increased risk of malnutrition and reduced prospects for education. AIDS is being blamed for declines in agricultural production in some countries.

Donor governments, non-governmental organizations, and African governments have responded primarily by attempting to reduce the number of new HIV infections, and by trying ameliorate the damage done by AIDS to families, societies, and economies. The adequacy of this response is the subject of much debate. Spending from all sources on HIV/AIDS in sub-Saharan Africa was estimated at $500 million for FY2000.

Treatment of AIDS sufferers with medicines that can result in long-term survival has not been widely used in Africa. Advocates of treatment argue that in view of recent drug price reductions, treatment is an affordable means of reducing AIDS damage to African economies, reinforcing prevention programs, and keeping parents alive. Skeptics argue that treatment is still too expensive to be an option for most Africans and would require costly improvements in Africa’s health infrastructure.

U.S. concern over AIDS in Africa grew during the 1980s, as the severity of the epidemic became apparent. According to the U.S. Agency for International Development, the United States has been the global leader in the international response to AIDS since 1986. Legislation enacted during the 106th Congress increased HIV/AIDS funding worldwide and supported several Africa AIDS initiatives.

MOST RECENT DEVELOPMENTS

The Senate passed its version of the Foreign Operations Appropriations (H.R. 2506) on October 24, 2001. The bill included $450 million for HIV/AIDS programs worldwide. For details, see Legislation section. A report from Zambia on October 17 indicated that AIDS was killing about 1,000 teachers each year, or nearly half the 2,200 new teachers graduated each year. A South African Medical Research Council report, released on October 16, predicted that South Africa’s death toll from AIDS would reach a cumulative total of between 5 and 7 million by 2010, when 780,000 people would be dying annually from the disease. Life expectancy would fall from 54 years at present to 41 by the end of the decade, according to the Council, which is government funded. South African officials, who had delayed release of the report, questioned its statistics and methodology and suggested that it was intended to promote the use of antiretroviral drugs, regarded by the government as unsafe.

BACKGROUND AND ANALYSIS

Sub-Saharan Africa has been far more severely affected by AIDS than any other part of the world. According to a December 1, 2000 report issued by the Joint United Nations Program on HIV/AIDS (UNAIDS), some 25.3 million adults and children are infected with the HIV virus in the region, which has about 10% of the world’s population but more than 70% of the worldwide total of infected people. The overall rate of infection among adults is about 8.8%, compared with 1.1% worldwide. UNAIDS projects that half or more of all 15 year-olds will eventually die of AIDS in some of the worst-affected countries, such as Zambia, South Africa, and Botswana, unless the risk of contracting the disease is sharply reduced. An estimated 17 million Africans have lost their lives to AIDS, and mortality is rising – 2.4 million Africans died of AIDS in 2000, compared with 2.2 million in 1999. AIDS has surpassed malaria as the leading cause of death in sub-Saharan Africa, and it kills many times more people than Africa’s armed conflicts.

Characteristics of the African Epidemic

In addition to its severity, the sub-Saharan AIDS epidemic is defined by a number of other unusual characteristics.

- HIV, the human immunodeficiency virus that causes AIDS, is spread in Africa primarily by heterosexual contact.
- Sub-Saharan Africa is the only region in which women are infected with HIV at a higher rate than men. According to UNAIDS, women make up an estimated 55% of the HIV-positive adult population in sub-Saharan Africa, as compared with 47% worldwide.
• Young women are particularly at risk. A U.N. study found girls aged 15-19 to be infected at a rate of 15% to 23%, while infection rates among boys of the same age were 3% to 4%.

• To date, eastern and southern Africa have been far more severely affected than West Africa, but infection rates in a number of West African countries are starting to escalate. In some southern African countries, 20% or more of the adult population is infected with HIV, and the rate has reached 35.8% in Botswana. On March 20, 2001, the South African government released statistics showing that 4.7 million South Africans, including 24.5% of adults, were infected with HIV/AIDS in 2000 – up from 22.4% in 1999. In West Africa, Senegal, with an active AIDS policy, had an adult infection rate below 2% in 1999, but the infection rate now exceeds 10% in Ivory Coast and is increasing in populous Nigeria as well.

• The African AIDS epidemic is having a much greater impact on children than is the case in other parts of the world. An estimated 600,000 African infants become infected with HIV each year through mother-to-child transmission, either at birth or through breast-feeding. (White House, Report on the Presidential Mission on Children Orphaned by AIDS in Sub-Saharan Africa: Findings and Plan of Action. Washington, July 19, 1999, p. 14.) These children have a short life expectancy, and the number of HIV-infected children currently alive in the region is currently estimated at 1 million (UNAIDS).

• A cumulative total of 12.1 million African “AIDS orphans” have lost either their mother or both parents to AIDS since the epidemic began, according to UNAIDS. A report by the U.S. Agency for International Development (USAID) puts the number of such orphans currently living in 26 African countries at 6.5 million, and projects that by 2010, there will be 15 million African AIDS orphans, including 2.7 million in Nigeria, 2.5 million in Ethiopia, and 1.8 million in South Africa. (Children on the Brink, 2000 update.) Because of the stigma attached to the AIDS disease, AIDS orphans run a greater risk of being malnourished, abused, and denied an education.

**Explaining the African Epidemic**

AIDS experts emphasize a variety of economic and social factors in explaining Africa’s AIDS epidemic, placing primary blame on the region’s poverty. Poverty has deprived Africa, for example, of effective systems of health information, health education, and health care. Thus, Africans suffer from a high rate of untreated sexually-transmitted infections (STIs) other than AIDS, and these increase susceptibility to HIV. African health care systems are typically unable to provide AIDS counseling, which could help slow the spread of the disease, and even HIV testing is difficult for many Africans to obtain. AIDS treatment is generally available only to the elite.

Poverty forces large numbers of African men to migrate long distances in search of work, and while away from home they may have multiple sex partners, increasing their risk
of infection. Some of these partners may be women who have become commercial sex workers because of poverty, and they too are highly vulnerable to infection. Migrant workers may carry the infection back to their wives when they return home. Long distance truck drivers, and drivers of “taxis,” who transport Africans long distances by car, are probably also key agents in spreading HIV.

Some behavior patterns in Africa may also be affecting the epidemic. In explaining the fact that young women are infected at a higher rate than young men, Peter Piot, the Executive Director UNAIDS, has commented that “the unavoidable conclusion is that girls are getting infected not by boys but by older men,” who are more likely than young men to carry the disease. (UNAIDS press release, September 14, 1999.) A researcher in a UNAIDS project studying the differential rate of infection added that “Young (women’s) lives are being cut short through sex which is all too often forced, coerced, or ‘bought’ with sugar-daddy gifts.” Many believe that the infection rate among women generally would be far lower if women’s rights were more widely respected in Africa and if women exercised more power in political and economic affairs. (For more on these issues, see Helen Epstein, “AIDS: the Lesson of Uganda,” New York Review of Books, July 5, 2001.)

The breakdown in social order and social norms caused by armed conflict could also be contributing to the African epidemic. Conflict, which has afflicted many sub-Saharan countries for years, is typically accompanied by numerous incidents of violence against women, including rape, carried out by soldiers and guerrillas. Such men are also more likely to resort to commercial sex workers than those living in a settled environment.

Some observers believe that the spread of AIDS in Africa could have been slowed if African leaders had been more engaged and outspoken in the struggle against the disease. President Yoweri Museveni of Uganda, in particular, has won wide recognition for leading a successful campaign against AIDS in his country. But many other African leaders have said or done comparatively little about the epidemic.

<table>
<thead>
<tr>
<th>Adult HIV Infection Rates, end of 1999 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Botswana 35.80</td>
</tr>
<tr>
<td>Swaziland 25.25</td>
</tr>
<tr>
<td>Zimbabwe 25.06</td>
</tr>
<tr>
<td>Lesotho 23.57</td>
</tr>
<tr>
<td>South Africa 19.94</td>
</tr>
<tr>
<td>Namibia 19.54</td>
</tr>
<tr>
<td>Zambia 19.95</td>
</tr>
<tr>
<td>Malawi 15.96</td>
</tr>
<tr>
<td>Kenya 13.95</td>
</tr>
<tr>
<td>Cent. Af. Republic 13.84</td>
</tr>
<tr>
<td>Mozambique 13.22</td>
</tr>
<tr>
<td>Djibouti 11.75</td>
</tr>
<tr>
<td>Burundi 11.32</td>
</tr>
<tr>
<td>Rwanda 11.21</td>
</tr>
<tr>
<td>Cote d’Ivoire 10.76</td>
</tr>
<tr>
<td>Ethiopia 10.63</td>
</tr>
<tr>
<td>Uganda 8.30</td>
</tr>
<tr>
<td>Tanzania 8.09</td>
</tr>
<tr>
<td>Cameroon 7.73</td>
</tr>
<tr>
<td>Burkina Faso 6.44</td>
</tr>
<tr>
<td>Congo Brazzaville 6.43</td>
</tr>
<tr>
<td>Togo 5.98</td>
</tr>
<tr>
<td>Congo Kinshasa 5.07</td>
</tr>
<tr>
<td>Nigeria 5.06</td>
</tr>
<tr>
<td>Gabon 4.16</td>
</tr>
<tr>
<td>Ghana 3.60</td>
</tr>
<tr>
<td>Sierra Leone 2.99</td>
</tr>
<tr>
<td>Eritrea 2.87</td>
</tr>
<tr>
<td>Liberia 2.80</td>
</tr>
<tr>
<td>Angola 2.78</td>
</tr>
<tr>
<td>Chad 2.69</td>
</tr>
<tr>
<td>Guinea Bissau 2.50</td>
</tr>
<tr>
<td>Benin 2.45</td>
</tr>
<tr>
<td>Mali 2.03</td>
</tr>
<tr>
<td>Gambia 1.95</td>
</tr>
<tr>
<td>Senegal 1.77</td>
</tr>
<tr>
<td>Guinea 1.54</td>
</tr>
<tr>
<td>Sudan .99</td>
</tr>
<tr>
<td>Mauritania .52</td>
</tr>
<tr>
<td>Equatorial Guinea .51</td>
</tr>
<tr>
<td>Somalia NA</td>
</tr>
<tr>
<td>Madagascar .15</td>
</tr>
</tbody>
</table>

President Daniel arap Moi of Kenya, where 13.9% of adults are infected and nearly a million people have died from AIDS, did not endorse the use of condoms as a preventive until December 1999. (Africa News Service, December 23, 1999.) South Africa has a large AIDS program launched by the former president, Nelson Mandela, who continues to speak out in support of preventive measures, but many critics doubt that the current president, Thabo Mbeki, is treating the disease with sufficient urgency. On April 19, 2000, the press reported that he had sent a letter to President Clinton and other heads of state asserting that Africa would not copy foreign approaches to dealing with AIDS and defending dissident scientists who maintain that AIDS is not caused by the HIV virus. Many health experts feared that Mbeki’s assertions that poverty was the underlying cause of AIDS, while in some sense partly true, would confuse South Africans, including poor South Africans, and keep them from taking measures that could prevent infection.

On October 15, 2000, Mbeki reportedly told top leaders of the ruling African National Congress that he would withdraw from the debate over HIV/AIDS. On March 14, 2001, President Mbeki rejected appeals in the national assembly that he declare the HIV/AIDS epidemic a national emergency. Such a declaration would have given the government expanded rights to obtain AIDS medications at lower prices under the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights. (See below, AIDS Treatment Issues.) South Africa has launched 18 pilot projects to treat HIV-positive pregnant women with the drug Nevirapine, which is being provided free by the German firm Boehringer-Ingelheim. Nevirapine is highly effective in preventing mother to child transmission of HIV. However, South Africa’s Treatment Action Campaign (TAC) launched a suit against the government on August 20, 2001, claiming that the pilot program was inadequate and demanding the establishment of a comprehensive, nationwide effort. According to TAC, 20,000 babies could be saved annually by such program.

Social and Economic Consequences

AIDS is having severe social and economic consequences in Africa, and these negative effects are expected to continue for many years. A January 2000 Central Intelligence Agency National Intelligence Estimate on the infectious disease threat, made public in an unclassified version, forecasts grave problems over the next 20 years.

At least some of the hardest-hit countries, initially in sub-Saharan Africa and later in other regions, will face a demographic catastrophe as HIV/AIDS and associated diseases reduce human life expectancy dramatically and kill up to a quarter of their populations over the period of this Estimate. This will further impoverish the poor, and often the middle class, and produce a huge and impoverished orphan cohort unable to cope and vulnerable to exploitation and radicalization. (CIA, The Global Infectious Disease Threat and Its Implications for the United States [http://www.odci.gov], “Publications and Reports”.)

The estimate predicted increased political instability and slower democratic development as a result of AIDS. According to the World Bank,

The illness and impending death of up to 25% of all adults in some countries will have an enormous impact on national productivity and earnings. Labor productivity is likely to drop, the benefits of education will be lost, and resources that would have been used for
investments will be used for health care, orphan care, and funerals. Savings rates will decline, and the loss of human capital will affect production and the quality of life for years to come. (World Bank, *Intensifying Action Against HIV/AIDS in Africa*.)

In the most severely affected countries, sharp drops in life expectancy are occurring, and these will reverse major gains achieved in recent decades. At AIDS2000, the July 2000 international AIDS conference held in Durban, South Africa, Karen Stanecki of the U.S. Census Bureau reported that AIDS had cut life expectancy in Botswana from 71 years to 39 and in Zimbabwe from 70 years to 38. Stanecki predicted that South Africa, Zimbabwe, and Botswana will begin to experience negative population growth in 2003, and that by 2010, life expectancy at birth will have fallen to about 30 years throughout southern Africa.

According to many reports, AIDS has devastating effects on rural families. The father is typically the first to fall ill, and when this occurs, farm tools and animals may be sold to pay for his care. As he grows weaker, he will become unable to farm at all; nor will his wife be able to farm, since she will be devoting her time to nursing him. The family will be unable to pay school fees, and in any event, children will likely be kept out of school to perform added chores at home. Should the mother also become ill, children may be forced to shoulder responsibility for the full time care of their parents. The economic consequences of the disruption of rural life can be severe, and reduced food production in some areas due to AIDS has been reported.

AIDS is also being blamed for shortages of skilled workers and teachers in several countries. Although unemployment is generally high in Africa, such trained personnel are not readily replaced. The disease is claiming many lives at middle and upper levels of management in both business and government.

AIDS may have serious security consequences for much of Africa, since HIV infection rates in many armies are extremely high. South African soldiers have been widely expected to play an important peacekeeping role in the Democratic Republic of the Congo (DRC, formerly Zaire) and perhaps other countries in coming months and years, but estimates of the infection rate in the South Africa army run from 17% to 40%, with higher rates reported for units based in heavily infected KwaZulu-Natal province. Infection rates among the seven armies currently embroiled in the conflict in the Democratic Republic of the Congo have been estimated at 50% or higher (*Report on the Presidential Mission on Children Orphaned by AIDS.*) The ability of armies facing heavy infection rates to conduct effective operations is a source of concern to analysts. Domestic political stability could also be threatened in African countries if the security forces become unable to perform their duties due to AIDS. (For more on this issue, see the CIA Estimate, noted above.)

**Responses to the AIDS Epidemic**

Donor governments, non-governmental organizations (NGOs) working in Africa, and African governments have responded to the AIDS epidemic primarily by attempting to reduce the number of new HIV infections, and to some degree, by trying ameliorate the damage done by AIDS to families, societies, and economies. A third possible response – treatment of AIDS sufferers with medicines that can result in long-term survival – has not been widely used in Africa, largely due to cost, although some treatment is now being offered at private
Clinics or through programs offered by a few large employers. Demands for large-scale treatment are mounting in Africa, and are drawing support from outside the continent among AIDS activists and others concerned for the region’s future. There is also growing support for expanded programs to treat opportunistic infections (OIs), such as tuberculosis, which can shorten the lives of HIV victims by years but can be treated or prevented by comparatively inexpensive drugs. An effective vaccine could offer a permanent solution to the African AIDS crisis, but progress in vaccine development has been slow. (For more information on the international response to the epidemic, see CRS Report RL30883, Africa: Scaling Up the Response to the HIV/AIDS Pandemic.)

Efforts to reduce the number of AIDS infections have focused on increasing AIDS awareness among Africans. Programs and projects aimed at combating the disease typically provide information on how the disease is spread— and on how it can be avoided— through the media, posters, lectures, and skits. Donor-sponsored voluntary counseling and testing (VCT) programs, where available, enable African men and women to learn their HIV status. Those testing positive are typically referred to support groups and advised on ways to protect others from contracting the disease; while the majority testing negative are counseled on behavior changes that will keep them HIV-free. USAID is currently supporting VCT centers in 10 African countries. AIDS awareness programs can be found in many African schools and increasingly in the workplace, where employers are recognizing their interest in reducing the infection rate among their employees. Many projects aim at making condoms readily available— USAID reports that it has shipped more than 2 billion condoms to Africa since 1986— and on providing instruction in condom use. Some recent pilot projects have had success in reducing mother-to-child transmission by administering the anti-HIV drug AZT, or a less expensive medicine, Nevirapine, during birth and early childhood.

Church groups and humanitarian organizations have helped Africa deal with the consequences of AIDS by setting up programs to provide care and education to orphans. The Farm Orphan Support Trust in Zimbabwe tries to keep sibling orphans together and in a family living situation; the Salvation Army sponsors a pilot, community-based, orphan support program in Zambia, providing education and health care to vulnerable children. (Report on the Presidential Mission on Children Orphaned by AIDS.) A United Nations study has found that community-based organizations, sometimes with the support of NGOs, have emerged to supply additional labor, home care for the sick, house repair, and other services to AIDS-afflicted families. (UNAIDS, A Review of Household and Community Responses to the HIV/AIDS Epidemic in Rural Areas of Sub-Saharan Africa, 1999.)

Public-private partnerships have also become an important vehicle for responding to the African AIDS pandemic. The Bill and Melinda Gates Foundation has been a major supporter of vaccine research and a variety of AIDS programs undertaken in cooperation with African governments and donors. The Rockefeller Foundation, working with UNAIDS and others, has sponsored programs to improve AIDS care in Africa, and both Bristol-Myers Squibb and Merck and Company have undertaken programs with the Botswana government aimed at improving the country’s health infrastructure.

Donors have made several recent pledges to scale up the international response to the AIDS epidemic. On July 23, 2000, leaders at the G-8 world economic summit in Okinawa pledged to reduce the number of young people infected by the HIV virus by 25%. The World Health Organization estimated that this pledge, and G-8 pledges to attack malaria and
tuberculosis as well, would cost at least $5 billion per year for 5 years. The World Bank, on September 12, 2000, made an initial commitment of $500 million to a Multi-Country HIV/AIDS Program (MAP) for Africa. The MAP, designed to be both flexible and rapidly disbursing, according to the Bank, will help fund HIV/AIDS prevention, care, and treatment programs in countries that have developed a strategic approach to combating the epidemic and that meet certain other conditions.

African heads of state, meeting in Abuja, Nigeria, issued a statement on April 27, 2001, declaring AIDS a continental emergency, pledging to spend 15% of their annual budgets on health and urging donors to create a $5 billion to $10 billion Global AIDS Fund. U.N. Secretary General Kofi Annan subsequently asked for the creation of a “war chest,” the Global AIDS and Health Fund, of $7 billion to $10 billion per year, primarily to fight HIV/AIDS but also to combat tuberculosis and malaria. By August 2001, $1.4 billion in one-time contributions had been pledged to the Fund, but it remains to be seen whether the fund soon reaches the annual amounts sought by the Secretary General. The structure of the new Global Fund is still under negotiation, but Annan has said that it will have a small secretariat as well as a board of directors, including representatives of donor and recipient governments, groups fighting the epidemic, and the private sector. The G-8 summit of industrialized nations, held in Genoa, July 20-22, endorsed the proposed fund and affirmed that members were committed to making it operational by the end of the year.

USAID estimates that in FY2000, all donors and lending agencies, together with African governments, spent approximately $500 million in combating AIDS. UNAIDS estimates, however, that African countries require about $1.5 billion for HIV/AIDS prevention programs, and another $1.5 billion for HIV/AIDS care, including orphan care. These estimates do not include any funding for AIDS treatment with antiretroviral drugs. (See below, AIDS Treatment Issues.) The funding issue is covered in detail in CRS Report RL30883, Africa: Scaling Up the Response to the HIV/AIDS Pandemic.

The United Nations convened a General Assembly Special Session on HIV/AIDS, June 25-27, in New York. Much of the debate at the session centered on the issue of whether large-scale treatment with antiretroviral drugs could be provided in Africa. The Special Session concluded with passage of a resolution emphasizing the need for “widespread and effective prevention,” but “recognizing that care, support, and treatment can contribute to effective prevention.” The resolution stated that strong government leadership is essential for an effective response and laid out a timetable for government action to develop and implement HIV/AIDS programs.

Further information on the response to AIDS in Africa may be found at the following web sites:

CDC: [http://www.cdc.gov/nchstp/od/nchstp.html]
European Union: [http://europa.eu.int/comm/development/aids/]
International AIDS Vaccine Initiative: [http://www.iavi.org]
International Association of Physicians in AIDS Care: [http://www.iapac.org/]
UNAIDS: [http://www.unaids.org/]
Effectiveness of the Response

The response to AIDS in Africa has had some successes, most notably in Senegal, mentioned above, and in Uganda, where the rate of infection has been cut in half – to approximately 8.3% – by an active AIDS awareness program that openly advocates the use of condoms. Despite these success stories, however, available evidence indicates that the epidemic is deepening in most of the region. In the West African nation of Nigeria, Africa’s most populous country with 111 million people, the rate of adult HIV infection increased from 4.5% in 1995 to 5.4% in 1999, and is reportedly nearing 7% in some parts of Lagos, the largest city.

A United Nations update on the AIDS epidemic, issued on December 1, 2000, estimated that there had been 3.8 million new HIV infections in Africa in 2000 as compared to 4 million in 1999, and suggested that the decrease could in part reflect the success of prevention programs in some countries. The report also noted, however, that the decline in new infections could have resulted partly from the fact that many of the most vulnerable, sexually active people had already been infected in prior years. In any event, citing Nigeria, the report warned that the epidemic could still take off in countries with comparatively low infection rates.

Experts note that there are a number of barriers to a more effective AIDS response in Africa, such as cultural norms that make it difficult for many government, religious, and community leaders to acknowledge or discuss sexual matters, including sex practices, prostitution, and the use of condoms. However, experts continue to advocate AIDS awareness and AIDS amelioration as essential components of the response to the epidemic. Indeed, there is strong support for an intensification of awareness and amelioration efforts, as well as adaptations to make such efforts more effective. With respect to amelioration, UNAIDS has recommended that donors find ways to strengthen those indigenous support institutions that are already helping AIDS victims and their families. (A Review of Household and Community Responses.) There is also support for a stronger focus on treatment of non-HIV sexually-transmitted infections, which can dramatically lower the rate of HIV transmission.

The lives of infected people could be significantly prolonged and improved, some maintain, if more were done to identify and treat the opportunistic infections, particularly tuberculosis, that typically accompany AIDS. Millions of Africans suffer dual infections of HIV and TB, and the combined infection dramatically shortens life. Tuberculosis can be cured by treatment with a combination of medications over several months, even in HIV-infected patients. However, according to the World Health Organization, Africans often delay seeking treatment for TB or do not complete the course of medication (Global Tuberculosis Control: WHO Report 1999, Key Findings), contributing to the high incidence of death among those with dual infections. Pfizer Corporation has signed an agreement with South Africa to donate the anti-fungal Diflucan (fluconazole) for treating AIDS-related opportunistic infections, including cryptococcal meningitis, a dangerous brain inflammation. In June 2001, the company announced that it would expand this program to 50 of the world’s least developed countries. UNAIDS and the World Health organization recommended on
April 5, 2000, that Africans infected with HIV be treated with an antibiotic/sulfa drug combination known by the trade name Bactrim in order to prevent opportunistic infections. Studies indicate that the drug could reduce AIDS death rates at a cost of between $8 and $17 per year per patient.

AIDS Treatment Issues

Access for poor Africans to costly combinations of AIDS medications or “antiretrovirals” (ARVs) is perhaps the most contentious issue surrounding the response to the African epidemic today. Administered in a treatment regimen known as HAART – highly active antiretroviral therapy – these drugs can return AIDS victims to normal life and lead to long-term survival rather than early death. Such treatment has proven highly effective in developed countries, including the United States, where AIDS, which had been the eighth leading cause of death in 1996 no longer ranked among the 15 leading causes by 1998. (U.S. Department of Health and Human Services Press Release, October 5, 1999.)

Advocates of making HAART widely available in Africa argue that the therapy would keep parents alive, slowing the growth in the number of AIDS orphans; and keep workers, teachers, civil servants, and managers alive as well, thus reducing the economic impact of the epidemic. Moreover, proponents argue, treatment will strengthen prevention efforts, since the possibility of treatment will create strong incentives for participation in VCT programs. Someone who enters treatment and is receiving regular medical attention, many believe, will be more likely to behave in ways that minimize the risk of spreading HIV. Some also see a moral obligation to try to save lives when the medications for doing so exist.

The high cost of HAART treatments, however, has been regarded as the principal obstacle to offering the therapy on a large scale in Africa, where most victims are poor and lack health insurance. The cost of administering HAART was once estimated at between $10,000 and $15,000 per person per year. On May 11, 2000, five major pharmaceutical companies announced that they were willing to negotiate sharp reductions in the price of AIDS drugs sold in Africa. UNAIDS launched a program in cooperation with the pharmaceutical companies to boost treatment access and, in June 2001, reported that 10 African countries had reached agreement with manufacturers. The agreements significantly reduced prices in exchange for health infrastructure improvements to assure that ARVs are administered safely. Patented AIDS medications are reportedly becoming available in several African countries, at prices ranging from several hundred dollars to just over $1000 per patient per year, for a three-drug treatment comparable to that available in developed countries. HAART is now available in private clinics in some African cities, and Uganda as well as Cote d’Ivoire are providing HAART in publicly-funded programs to several hundred patients.

The degree to which Africa’s poorly developed health infrastructure prevents the wider availability of HAART is controversial. AIDS activists believe that millions of Africans could quickly be given access to AIDS drugs. Others maintain that African supply channels cannot make the drugs consistently available to millions of patients and that regular monitoring of patients by medical personnel is unavailable in much of the continent. Monitoring is necessary, they maintain, to deal with side effects and to adjust medications if drug resistance emerges. Many fear that if the drugs are taken irregularly, resistant strains will emerge that could cause untreatable infections worldwide.
Harvard University faculty released a “consensus statement” on April 4, 2001, maintaining that objections to widespread treatment of HIV-infected people in low-income countries with antiretroviral drugs were not valid. The statement, available online at [http://www.cid.harvard.edu], called for an initial effort to treat at least one million AIDS patients in Africa within 3 years.

Many also advocate “parallel imports” of drugs and “compulsory licensing” by African governments to lower the price of patented medications. Through parallel importing, patented pharmaceuticals could be purchased from the cheapest source, rather than from the manufacturer; while under “compulsory licensing,” an African government could order a local firm to produce a drug and pay a negotiated royalty to the patent holder.

Although both parallel imports and compulsory licensing are permitted under Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS agreement) of the World Trade Organization agreement for countries facing national emergencies, U.S. officials once strongly opposed such measures on grounds that they could lead to infringements of intellectual property rights. Advocates for the pharmaceutical companies argued that parallel importing and compulsory licensing could reduce profits, and that this would hinder the ability of manufacturers to conduct research on new drugs, including drugs that might be even more effective against HIV. A third view has been that some combination of subsidization, price reduction, and local manufacturing might be found that would make the drugs much more widely available while maintaining drug company revenues through the sheer volume of African sales.

On May 10, 2000, President Clinton issued an executive order stating that the United States would not seek to prevent sub-Saharan countries from promoting access to HIV/AIDS pharmaceuticals or medical technologies consistent with the World Trade Organization’s TRIPS agreement. On February 22, 2001, an official of the U.S. Trade Representative’s office said the Bush Administration was not considering any change in current “flexible policy” on this issue.

In South Africa, a suit by a consortium of pharmaceutical manufacturers against the South African government became a focal point for the debate over the price of AIDS medications in poor countries in the first months of 2001. The suit was directed against the South African Medicines Act, which would allow the health minister to authorize importation of generic copies of patented medications – a provision the drug companies argued violated South Africa’s own constitution and patent laws. The stance of the companies drew widespread protests, and on April 19, 2001, all 39 plaintiffs agreed to drop their suit. The South African government did not immediately move to import generic AIDS medications, however, and is cooperating with manufacturers in drafting regulations to implement contentious portions of the Medicines Act.

In September 2001, Nigeria launched a program to treat 10,000 HIV-infected adults and 5,000 children with antiretrovirals supplied by Cipla, an India-based pharmaceutical manufacturer that copies patented drugs. At least 2.6 million Nigerians are believed to be infected, and the program is expected to grow rapidly.
U.S. Policy

A July 2000 Washington Post article called into question the adequacy and timeliness of the early U.S. response to the HIV/AIDS threat in Africa. (Barton Gellman, “The Global Response to AIDS in Africa: World Shunned Signs of Coming Plague.” Washington Post, July 5, 2000). Nonetheless, U.S. concern did begin to mount during the 1980s, as the severity of the epidemic became apparent. In 1987, in acting on the FY1998 foreign operations appropriations legislation, Congress earmarked funds for fighting AIDS worldwide, and House appropriators noted that in Africa, AIDS had the potential for “undermining all development efforts” to date (H.Rept. 100-283). In subsequent years, Congress supported AIDS spending at or above levels requested by the executive branch, either through earmarks or report language.

USAID states that it has been the global leader in the international response to AIDS since 1986, not only by supporting multilateral efforts but also by directly sponsoring regional and bilateral programs aimed at combating the disease. (See USAID’s Web site at [http://www.usaid.gov/], click on “Population, Health, and Nutrition.”) The Agency has sponsored AIDS education programs; trained AIDS educators, counselors, and clinicians; supported condom distribution; and sponsored AIDS research. USAID claims several successes in Africa, such as helping to reduce HIV prevalence among young Ugandans and to prevent an outbreak of the epidemic in Senegal; reducing the frequency of sexually transmitted infections in several African countries; sharply increasing condom availability in Kenya and elsewhere; assisting children orphaned by AIDS; and sponsoring the development of useful new technologies, including the female condom. USAID reports that it spent a total of $67 million on fighting AIDS in Africa in FY1998 and $81 million in FY1999. In addition, some spending by the Department of Health and Human Services was going toward HIV surveillance in Africa and other Africa AIDS-related efforts.

As the severity of the epidemic continued to deepen in recent years, many of those concerned for Africa’s future, both inside and outside government, came to feel that more should be done. On July 19, 1999, Vice President Gore proposed $100 million in additional spending for a global LIFE (Leadership and Investment in Fighting an Epidemic) AIDS initiative to begin in FY2000, with a heavy focus on Africa. Funds approved during the FY2000 appropriations process supported most of this initiative.

On June 27, 2000, the Peace Corps announced that all volunteers serving in Africa would be trained as AIDS educators and that 200 former volunteers would be sent to Africa through the Crisis Corps to work in AIDS care and prevention. Fifty new volunteers will work exclusively on AIDS-related projects in eastern and southern Africa.

The U.S. Export-Import Bank announced on July 19, 2000, that it would make available $1 billion in loans per year to finance the purchase in sub-Saharan African countries of HIV/AIDS medications, as well as related equipment and services, from U.S. firms. The 5-year loans would be at commercial interest rates, although some small pieces of financing costs might include an element of concessionality, according to the agency. Some criticized this offer on grounds that it would burden African countries with added debt and divert scarce resources to the purchase of costly antiretroviral drugs. Several African governments reportedly rejected the loans. Nonetheless, the Bank has reported some recent interest in such loans, which can be used to build health infrastructure and not just to buy medicines.
Table 1, which compares HIV/AIDS spending in FY2000 with projected spending in FY2001, indicates that spending through the prevention programs of the Centers for Disease Control (CDC) of the Department of Health and Human Services has increased significantly. In addition, the Defense Department has undertaken a new HIV/AIDS education program with African armed forces (see CRS Report RL30761, *HIV-1/AIDS and Military Manpower Policy*), while the Department of Labor (DoL) has launched a program to support AIDS education in the African workplace. In FY2001, USAID is targeting three heavily affected African countries – Kenya, Uganda, and Zambia – for a rapid scale up in HIV/AIDS activities intended to show measurable results in one to two years. Ten African countries have been identified for “intensive focus” to reduce prevalence rates as well as mother-to-child transmission and to increase support services for people living with or affected by AIDS within 3 to 5 years. USAID will maintain basic programs, including technical assistance, training, and provision of commodities in eight other African countries. The General Accounting Office released a report in March 2001 calling on USAID to develop better measures for evaluating the effectiveness of its HIV/AIDS programs in Africa. (GAO Report GAO-01-449, *U.S. Agency for International Development Fights AIDS in Africa, but Better Data Needed to Measure Impact.*)

<table>
<thead>
<tr>
<th></th>
<th>FY2000</th>
<th>FY2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>USAID</td>
<td>134</td>
<td>144</td>
</tr>
<tr>
<td>CDC</td>
<td>34</td>
<td>77</td>
</tr>
<tr>
<td>DoD</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>DoL</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>168</td>
<td>229</td>
</tr>
</tbody>
</table>

**Table 1. U.S. Spending on Fighting AIDS in Africa**

($ millions)

**Bush Administration**

On May 11, 2001, President Bush announced that the United States would make a “founding contribution” of $200 million to the Global AIDS and Health fund proposed by U.N. Secretary General Kofi Annan. Additional funding would follow, the President said, “as we learn where our support can be most effective.” The President added that “we believe the fund must respect intellectual property rights, as an incentive for vital research and development.”

Prior to this announcement, the Administration had proposed $486.5 million in FY2002 for bilateral worldwide AIDS spending, including $360 million to be appropriated under the Foreign Operations appropriation for USAID programs, $116.5 million under the Health and Human Services appropriation for CDC programs, and $10 million in food aid. Proposed allocations of this FY2002 bilateral AIDS spending for Africa, and for particular countries, have not been released, but in FY2001, Africa is budgeted for just over 50% of worldwide
bilateral spending by all agencies. No funds were requested for the DoD program in FY2002. The House-passed version of the Foreign Operations Appropriations (H.R. 2506) includes more funding for worldwide HIV/AIDS programs than the Administration requested.

After President Bush’s May 11 announcement of a $200 million pledge to the Global AIDS and Health Fund, some AIDS activists and others criticized the amount as too small to make a significant difference in the African HIV/AIDS pandemic. Others argued, however, that the Administration was taking a first step in what could turn out to be a major long-term commitment. On June 11, 2001, the Administration submitted a request for FY2002 budget amendments to fund its pledge, identifying transfers totaling $100 million from HHS and $100 million from foreign assistance programs, which it said would not have serious programmatic impacts. Subsequently, however, Congress appropriated $100 million for the fund under the Supplemental Appropriations Act (P.L. 107-20/H.R. 2216). The House-passed version of the Foreign Operations Appropriations legislation would permit another $100 million to be contributed, with the funds to come from FY2001 and FY2002 Child Survival account of the Development Assistance program. The Senate-passed version would permit $90 million to be donated to the Fund from the $450 million set aside in Child Survival funds for worldwide HIV/AIDS programs. Other support for the Fund might be available through the appropriations for the Department of Health and Human Services (see Legislation section).

Some concern has been expressed about using $200 million to provide resources to a new international organization, as yet to be established, rather than to augment the HIV/AIDS resources of USAID and CDC, which many regard as more effective than other organizations and agencies in coping with the African pandemic. Others argue that despite the experience and capabilities of USAID and CDC, it is important to establish an overarching international body that may eventually be able to coordinate and integrate the activities of all donors. (For critiques of the fund proposal, see the Christian Aid policy brief “False Dawn” at [http://www.christian-aid.org.uk/], and The Lancet, August 18, 2001).

Secretary of State Colin Powell told the United Nations General Assembly Special Assembly on June 25, 2001, that the global response to the pandemic had been “woefully inadequate” to date. Noting the U.S. pledge for the Global Fund, Powell affirmed that “more will come from the United States as we learn where our support can be most effective.” The Secretary of State, also noting U.S. bilateral HIV/AIDS programs and vaccine research, called for an integrated approach, emphasizing prevention but also including treatment, orphan care, affordable drugs, and health infrastructure.

Legislative Action

In August 2000, the Global AIDS and Tuberculosis Relief Act of 2000 (P.L. 106-264) became law. This legislation authorizes $300 million for each of fiscal years 2001 and 2002 for a comprehensive, coordinated, worldwide HIV/AIDS effort under USAID, not less than 65% to be available through non-governmental organizations, including religious-affiliated organizations, and not less than 20% to be available for a multi-donor strategy to address the support and education of orphans in sub-Saharan Africa. The Foreign Operations appropriations legislation (P.L. 106-429) provides $300 million – somewhat more than initially requested by the Clinton Administration – for HIV/AIDS programs worldwide in FY2001. The appropriation also provides $10 million for the International AIDS Vaccine Initiative. The Department of Defense (DoD) appropriations (P.L. 106-259) earmarks the
$10 million requested by the Clinton Administration for HIV/AIDS education programs with African armed forces. In addition, the Agriculture appropriation (P.L. 106-387) provides $25 million in food aid to assist foreign countries in mitigating the effects of the epidemic.

In 2001, a number of bills have been introduced with HIV/AIDS related provisions. These include:

H.R. 684 (Millender-McDonald), to authorize assistance for mother-to-child HIV/AIDS transmission prevention efforts.
H.R. 933 (Waters), Affordable HIV/AIDS Medicines for Poor Countries Act.
H.R. 1567 (Lee), to encourage the provision of multilateral debt cancellation for countries eligible to be considered for assistance under the Heavily Indebted Poor Countries (HIPC) Initiative or heavily affected by HIV/AIDS, and for other purposes.
H.R. 1642 (Waters), Debt Cancellation for the New Millennium Act.
H.R. 2104 (Eddie Bernice Johnson), to amend the Foreign Assistance Act of 1961 to authorize the provision of education and related services to law enforcement and military personnel of foreign countries to prevent and control HIV/AIDS and tuberculosis.
H.R. 2604 (Bereuter), to authorize the United States to participate in and contribute to the seventh replenishment of the resources of the Asian Development Fund and the fifth replenishment of the resources of the International Fund for Agricultural Development, and to set forth additional policies of the United States towards the African Development Bank, the African Development Fund, the Asian Development Bank, the Inter-American Development Bank, and the European Bank for Reconstruction and Development. Includes a section on an HIV/AIDS Strategic Plan.
S. 1120 (Boxer), Global AIDS Research and Relief Act of 2001.
S. 1230 (Frist/Clinton), Global Leadership in Developing the Expanded Response Act, or the “GLIDER Act.”

Bills that have been reported out of committee or received floor action are detailed below, under Legislation.
LEGISLATION

H.Con.Res. 102 (Leach)/S.Con.Res. 53
Hunger to Harvest Resolution: A Decade of Concern for Africa. States the sense of Congress that Congress should undertake a multi-year commitment with other donors to reverse current levels of hunger in sub-Saharan Africa, with funding directed, among other purposes, toward efforts to prevent, treat, and control HIV/AIDS. Introduced on April 4, 2001, and referred to the House Committee on International Relations. Somewhat similar Senate version states sense of Congress that within 90 days the President should submit a report setting forth a five-year strategy to reverse hunger and poverty in Africa. Senate version introduced on June 21, 2001; referred to the Committee on Foreign Relations. Reported July 12 without report. Passed the Senate by unanimous consent, July 18. Received in the House and held at the desk, July 19.

H.R. 1646 (Hyde)
Department of State Authorization. Authorizes up to $1 million for HIV/AIDS research and mitigation strategies in a Border-Less World academic program of the Fulbright Academic exchange program; states the sense of Congress that U.S. officials should urge the United Nations to adopt an HIV/AIDS mitigation strategy as a component of U.N. peacekeeping operations; and that the Secretary of State should establish an international HIV/AIDS intervention, mitigation, and coordination task force. Introduced on May 4, 2001; referred to the Committee on International Relations; marked up and ordered reported, May 2; report filed (H.Rept. 107-57); passed the House, May 16, received in the Senate and referred to the Committee on Foreign Relations, May 17.

H.R. 2069 (Hyde)
Global Access to HIV/AIDS Prevention, Awareness, Education, and Treatment Act of 2001. States the sense of Congress that the United States should provide additional funds for multilateral programs and efforts to combat HIV/AIDS, including programs that make available pharmaceuticals and diagnostics for HIV/AIDS therapy in sub-Saharan Africa; and that programs to help AIDS orphans as well as micro-enterprise programs for HIV/AIDS affected families should be expanded; amends the Foreign Assistance Act of 1961 (P.L. 87-195) to state that HIV/AIDS assistance should include prevention (including assistance through faith-based organizations), treatment, monitoring, and related activities; requires an annual report on USAID HIV/AIDS activities; authorizes $560 million for these activities in each of fiscal years 2002 and 2003; requires USAID to assist sub-Saharan and other developing countries to procure and distribute HIV/AIDS pharmaceuticals, including antiretrovirals, and authorizes $50 million for this purpose; states that the President shall establish an inter-agency task force to coordinate international HIV/AIDS activities; establishes a permanent Global Health Advisory Board to assist in the development and implementation of international health programs; authorizes $750 million in FY2002 for contributions to a global health fund or other multilateral efforts to prevent and treat HIV/AIDS. Introduced on June 6, 2001; referred to the Committee on International Relations; amendment in the nature of a substitute marked up and approved by the House International Relations Committee, June 27, 2001; reported (H.Rept. 107-137) July 12.
**H.R. 2330 (Bonilla)**


**H.R. 2506 (Kolbe)**

Foreign Operations, Export Financing, and Related Programs Appropriations Act, 2002. As reported in the House on July 17, 2001, (H.Rept. 107-142), earmarked $434 million under the Child Survival and Health Programs Fund for HIV/AIDS worldwide; amendment by Rep. Visclosky to increase this amount by $13 million approved (258-162), July 24; provides, according to report language, another $40 million for fighting HIV/AIDS through other USAID-managed accounts, such as the Economic Support Fund and International Disaster Assistance; earmarks $10 million in Child Survival funds for a contribution to the International AIDS Vaccine Initiative; permits up to $100 million in FY2001 and FY2002 Child Survival funds as a U.S. contribution to a multilateral trust fund to fight HIV/AIDS, malaria, and tuberculosis. Senate-passed version sets aside $450 million in Child Survival funds for HIV/AIDS worldwide, including up to $90 million for a U.S. contribution to a global HIV/AIDS, malaria, and tuberculosis fund; states that not less than $15 million of the $450 million should be made available to support the development of microbicides; earmarks $10 million in Child Survival funds for a contribution to the International AIDS Vaccine Initiative; provides, according to report language, another $25 million worldwide for HIV/AIDS through other programs, such as the Economic Support Fund. Bill passed the House (381-46), July 24; received in the Senate and referred to the Committee on Appropriations, July 25; ordered to be reported with an amendment in the nature of a substitute, July 26; reported (S.Rept. 107-58) September 4; passed the Senate (96-2), October 24; Senate appointed conferees, October 24.

**H.R. 3061 (Regula)/S. 1536 (Harkin)**

Departments of Labor, Health and Human Services, and Education Appropriations. House bill appropriate $137.527 million for the global HIV/AIDS programs of the Centers for Disease Control and Prevention of the Department of Health and Human Services; permits the transfer of up to $25 million from the National Institute of Allergy and Infectious Diseases (NIAID) to the Global Fund to Fight HIV/AIDS, Malaria, and Tuberculosis; permits the transfer of up to $75 million from the Fund to the buildings and facilities account of the National Institutes of Health (NIH). Senate version appropriates $154.527 million for CDC global HIV/AIDS programs; transfers to the global fund $25 million from NIAID, $70 million from NIH buildings and facilities, and $5 million from general departmental management. H.R. 3061 reported as an original measure (H.Rept. 107-229) on October 9, 2001. Passed the House (373-43), October 11. Received in the Senate, October 15. S. 1536 reported as an original measure (S.Rept. 107-84), October 11.